Applications of Non-Coding RNAs in Patients With Retinoblastoma

Daniel Fernandez-Diaz; Cristina Rodriguez-Vidal; Paula Silva-Rodríguez; Laura Paniagua; María José Blanco-Teijeiro; María Pardo; Antonio Piñeiro; Manuel Bande

doi:10.3389/fgene.2022.842509

Applications of Non-Coding RNAs in Patients With Retinoblastoma

Front Genet. 2022 Mar 31:13:842509. doi: 10.3389/fgene.2022.842509. eCollection 2022.

Authors

Daniel Fernandez-Diaz^{1

2}, Cristina Rodriguez-Vidal³, Paula Silva-Rodríguez^{2

4}, Laura Paniagua⁵, María José Blanco-Teijeiro^{1

2}, María Pardo^{2

6}, Antonio Piñeiro^{1

2}, Manuel Bande^{1

2}

Affiliations

¹ Department of Ophthalmology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
² Tumores Intraoculares en el Adulto, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.
³ Department of Ophthalmology, University Hospital of Cruces, Barakaldo, Spain.
⁴ Fundación Pública Galega de Medicina Xenómica, Clinical University Hospital, Santiago de Compostela, Spain.
⁵ Department of Ophthalmology, University Hospital of Coruña, A Coruña, Spain.
⁶ Grupo Obesidómica, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.

Abstract

Retinoblastoma (RB) is the most common primary intraocular malignancy in childhood. In the carcinogenic process of neoplasms such as RB, the role of non-coding RNAs (ncRNAs) has been widely demonstrated recently. In this review, we aim to provide a clinical overview of the current knowledge regarding ncRNAs in relation to RB. Although ncRNAs are now considered as potential diagnostic biomarkers, prognostic factors, and therapeutic targets, further studies will facilitate enhanced understanding of ncRNAs in RB physiopathology and define the roles ncRNAs can play in clinical practice.

Keywords: circRNA; diagnostic biomarker; lncRNA; miRNA; non-coding RNA; prognostic factor; retinoblastoma; therapeutic target.

Publication types

Review